Science

Yüksel Ürün: New Player in ARPI-Resistant Prostate Cancer

Yüksel Ürün/X

Jun 30, 2025, 14:40

Yüksel Ürün: New Player in ARPI-Resistant Prostate Cancer

Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X about a paper by Dongyin He et al. published in PNAS:

“New player in ARPI-resistant prostate cancer!

HEAL-116, a next-gen 3βHSD1 inhibitor, shows potent tumor suppression, synergy with abiraterone/enzalutamide, and high oral bioavailability.

Structure-guided. Clinically promising.”

Title: Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy

Authors: Dongyin He, Luyao Zhang, Leiye Yu, Yuhang Zhang, Jingjing Chen, Leibo Wang, Haoran Hu, Hongyu Liu, Hong Zheng, Jixin Xia, Jiahui Chen, Chenhui Li, Xin Li, Huiru Tang, Jia Liu, Ruobing Ren, Youhong Hu, Zhenfei Li.

You can read the Full Article in PNAS.

Yüksel Ürün: New Player in ARPI-Resistant Prostate Cancer

More posts featuring Yüksel Ürün.

ARPI-resistant prostate cancer cancer Chenhui Li Dongyin He Haoran Hu Hong Zheng Hongyu Liu Huiru Tang Jia Liu Jiahui Chen Jingjing Chen Jixin Xia Leibo Wang Leiye Yu Luyao Zhang OncoDaily Oncology prostate cancer Ruobing Ren Xin Li Youhong Hu Yuhang Zhang Yüksel Ürün Zhenfei Li

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Kevin Conroy: Oncodetect is Now Covered by Medicare in Stage IV Colorectal Cancer